Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom Population (ACEL-UK): Cohort Study - Takeaways - MDSpire

Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom Population (ACEL-UK): Cohort Study

  • By

  • Mia Holley

  • Salman Razvi

  • Ian Maxwell

  • Rosie Dew

  • Scott Wilkes

  • April 3, 2025

  • 0 min

Share

  • 1

    Levothyroxine (LT4) therapy in older adults with subclinical hypothyroidism (SCH) shows a protective effect against cardiovascular events.

  • 2

    LT4 therapy is associated with an increased risk of bone events and all-cause mortality in older adults with SCH.

  • 3

    The study included 53,899 patients, with a median follow-up duration of 10 years, highlighting the long-term effects of LT4.

  • 4

    Current reference intervals for TSH do not account for age, potentially leading to overdiagnosis and overtreatment in older adults.

  • 5

    The findings emphasize the need for careful consideration of the risks and benefits of LT4 therapy in older patients with SCH.

Original Source(s)

Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom Population (ACEL-UK): Cohort Study

  • by Mia Holley, Salman Razvi, Ian Maxwell, Rosie Dew, Scott Wilkes

  • April 3, 2025

Related Content

Radiomic Analysis Based on MRI Sequences for Identifying Spinal Bone Density Loss

Lower preoperative vitamin D levels are associated with poor clinical outcomes in elderly patients with osteoporotic vertebral compression fractures after percutaneous vertebroplasty

Evaluating the reliability and quality of osteoporosis content on TikTok and BiliBili: A cross-sectional content analysis